Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping ...

FRANKFURT, Germany (AP) — Pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post “for a period to support a smooth ...

The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post “for a period to support a smooth ...

May 12 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Sunday its drug Zepbound was superior to Novo Nordisk's (NOVOb.CO), opens new tab Wegovy across five weight-loss targets such as ...

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their waists compared with Novo Nordisk’s rival Wegovy. Barbara ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

Novo Nordisk (NYSE:NVO) shares dropped 5% in early ... delivered stronger results than Wegovy. In the 72-week SURMOUNT-5 study, patients taking Zepbound saw an average weight loss of 20.2%.